Clinical Trials

Anal

BrUOG 276: A phase II evaluation of ADXS11-001, Mitomycin, 5-fluoruracil (5-FU) and IMRT for anal cancer

Breast:

BrUOG 291: Five Fraction Partial Breast Irradiation using Non-Invasive Image-Guided Breast Brachytherapy (NIBB) 

Bladder:

BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin 

Colorectal:

BrUOG CR-261: Aflibercept Maintenance for Patients with Resected or Ablated Metastatic Colorectal

BrUOG 265: Phase I and Pharmacology Studies of Oral 5-iodo-2-pyrimidinone-2’-deoxyribose(IPdR) as a Prodrug for IUdR-mediated Tumor Radiosensitization in Gastrointestinal (GI) Cancers 

HEME:

BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma 

Lung

BrUOG 301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases 

Pancreatic:

BrUOG 292: FOLFOX-A For Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial 

BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial 

More information regarding these current ongoing research studies can be found at the National Cancer Institute.